Title: Methods and Compositions for Treating Gain-of-Function Disorders Using RNA Interference
Filed: April 6, 2005
Lead Inventor: Zuoshang Xu, University of Massachusetts (RXi Pharmaceuticals)
The invention, the patent's abstract states, "relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase, which causes inherited amyotrophic lateral sclerosis, with [an] RNAi agent. The invention further provides RNAi-resistant replacement genes containing mismatches with their respective RNAi agents, [as well as] vectors that express RNAi agent and RNAi- resistant replacement gene of the … invention."
Title: Methods of Identifying Genes Involved in Memory Formation Using Small Interfering RNA
Filed: May 15, 2008
Lead Inventor: Roderick Euan Milne Scott, Helicon Therapeutics
The invention, the patent application's abstract states, "relates to a method of identifying a gene or gene product associated with transcription-dependent memory formation in an animal." This method involves "administering to said animal sufficient small interfering RNA specific for the gene to inhibit gene function; training said animal under conditions sufficient to induce transcription-dependent memory formation in a normal untreated animal; and determining the level of transcription-dependent memory formation induced by the training of the treated animal," it notes.
The invention also "provides methods of using small interfering RNAs in hippocampus to identify genes and gene product whose inhibition affects contextual and temporal long-term memory, but not short-term memory," the abstract adds.
Title: Oligonucleotide-Core Carrier Composition for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same
Filed: Aug. 19, 2008
Lead Inventor: Gerardo Castillo, PharmaIn
According to the patent application's abstract, the invention "relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules."
Title: Regulatable Fusion Promoters
Filed: Sept. 29, 2006 PCT Filed: Sept. 29, 2006
Inventor: Charles Stout
The patent application, its abstract states, claims "fusion promoters … that combine [an] RNA polymerase III basal promoter and regulatory elements from RNA polymerase II regulatory regions, and which provide specific regulation of expression from the promoter. Such fusion promoters are useful, for example, for expressing RNAi agents in vivo."
Title: Compositions and Methods for Inhibiting CAR Gene Expression by RNA Interference
Filed: July 31, 2008
Lead Inventor: Tomoya Yamada, Sumitomo Chemical Company
The invention "provides short interfering ribonucleic acid, compositions, and methods for inhibiting the CAR gene expression simply and rapidly, which can be used for evaluating toxicity of a chemical substance," the patent application's abstract states.
Title: Novel Oligonucleotide Compositions and Probe Sequences Useful for Detection and Analysis of microRNAs and Their Target mRNAs
Filed: July 28, 2008
Lead Inventor: Irena Naguibneva, Centre National de la Recherche Scientifique
"The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs," the patent application's abstract states. "The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g. alterations associated with human disease, such as cancer."
Title: Compositions and Methods for Inhibiting the Expression of Anti-Apoptotic Genes
Filed: July 18, 2008
Inventor: Hans-Peter Vornlocher, Alnylam Europe (Alnylam Pharmaceuticals)
The invention, the patent application's abstract states, "relates to a double-stranded ribonucleic acid for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell."
Title: RNAi-Mediated Inhibition of Aquaporin 1 for Treatment of Ocular Neovascularization
Filed: Jan. 28, 2008
Lead Inventor: Rajkumar Patil, Alcon
The patent application, its abstract states, claims "RNA interference … for inhibition of aquaporin 1 to treat conditions associated with neovascularization."
Title: RNAi-Mediated Knockdown of NuMA for Cancer Therapy
Filed: June 3, 2008
Lead Inventor: Murali Addepalli, Reliance Life Sciences
"This invention relates to the use of short interfering nucleic acid molecules to inhibit nuclear mitotic apparatus protein gene expression and their use in treatment of disease, including cancer," the patent application's abstract states.